公开(公告)号：US20240287046A1

公开(公告)日：2024-08-29

申请号：US18604397

申请日：2024-03-13

Applicant: Full-Life Technologies HK Limited

Inventor： Fa LIU

IPC: C07D403/12 ,  A61K31/4155 ,  A61K51/04 ,  A61P35/00

CPC classification number: C07D403/12 ,  A61K31/4155 ,  A61K51/0482 ,  A61P35/00

Abstract: The present application relates to a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, or a radionuclide complex comprising a compound of Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions thereof. The present application also includes methods of using the compounds, complexes and compositions for targeting neurotensin receptors, and further to their use in the imaging, diagnosis and treatment of diseases, disorders or conditions such as cancer. The present application relates to a compound of Formula (II) or a pharmaceutically acceptable salt and/or solvate thereof, and to compositions and uses thereof, for example, in the treatment of diseases, disorders or conditions such as cancer.

公开(公告)号：US20240382630A1

公开(公告)日：2024-11-21

申请号：US18604400

申请日：2024-03-13

Applicant: Full-Life Technologies HK Limited

Inventor： Fa LIU ,  Alla DARWISH

IPC: A61K51/04

Abstract: The present application relates to a compound or a pharmaceutically acceptable salt and/or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and/or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and/or killing target cells. For example, the compound includes a compound of Formula I

公开(公告)号：US20250026739A1

公开(公告)日：2025-01-23

申请号：US18895915

申请日：2024-09-25

Applicant: Full-Life Technologies HK Limited

Inventor： Fa LIU

IPC: C07D403/12 ,  A61K31/4155 ,  A61K51/04 ,  A61P35/00

Abstract: The present application relates to a compound of Formula I or a pharmaceutically acceptable salt and/or solvate thereof, or a radionuclide complex comprising a compound of Formula I or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions thereof. The present application also includes methods of using the compounds, complexes and compositions for targeting neurotensin receptors, and further to their use in the imaging, diagnosis and treatment of diseases, disorders or conditions such as cancer. The present application relates to a compound of Formula II or a pharmaceutically acceptable salt and/or solvate thereof, and to compositions and uses thereof, for example, in the treatment of diseases, disorders or conditions such as cancer.